|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
For the quarterly period ended:
|
|
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
For the transition period from
|
to
|
|
|
|
|
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification Number)
|
|
Registrant’s telephone number, including area code:
|
(
|
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
|
|
|
Accelerated Filer ☐
|
Non-Accelerated Filer ☐
|
|
Smaller Reporting Company
|
Emerging Growth Company
|
|
Class
|
Outstanding at April 24, 2024
|
|
|
Common Stock, par value $0.10 per share
|
|
|
Page No.
|
||
|
PART I. FINANCIAL INFORMATION:
|
||
|
Item 1.
|
Financial Statements:
|
|
|
|
||
|
1
|
||
|
|
||
|
2
|
||
| |
||
|
3
|
||
| |
||
|
4
|
||
|
|
||
|
5
|
||
|
6
|
||
|
Item 2.
|
12 |
|
|
Item 3.
|
16
|
|
|
Item 4.
|
16
|
|
|
PART II. OTHER INFORMATION:
|
||
|
Item 1.
|
16
|
|
|
Item 1A.
|
16
|
|
|
Item 2.
|
16
|
|
|
Item 5.
|
16
|
|
| Item 6 |
Exhibits. | 16 |
|
17
|
||
|
18
|
||
| PART I. |
FINANCIAL INFORMATION
|
| ITEM 1. |
FINANCIAL STATEMENTS
|
|
Three Months
Ended March 31,
|
||||||||
|
2024
|
2023
|
|||||||
|
Revenue
|
$
|
|
$
|
|
||||
|
Cost of products sold
|
|
|
||||||
|
Selling and administrative expenses
|
|
|
||||||
|
Operating income
|
|
|
||||||
|
Interest expense
|
|
|
||||||
|
Earnings before income taxes
|
|
|
||||||
|
Income taxes
|
|
|
||||||
|
Net earnings
|
$
|
|
$
|
|
||||
|
Weighted average number of common shares outstanding:
|
||||||||
|
Basic
|
|
|
||||||
|
Diluted
|
|
|
||||||
|
Earnings per common share:
|
||||||||
|
Basic
|
$
|
|
$
|
|
||||
|
Diluted
|
$
|
|
$
|
|
||||
|
Dividends declared per common share
|
$
|
|
$
|
|
||||
|
Three Months
Ended March 31,
|
||||||||
|
2024
|
2023
|
|||||||
|
Comprehensive income
|
$
|
|
$
|
|
||||
| |
March 31,
2024
(Unaudited)
|
December 31,
2023
|
||||||
| Assets |
||||||||
|
Current Assets:
|
||||||||
|
Cash and cash equivalents
|
$
|
|
$
|
|
||||
|
Trade accounts receivable
|
|
|
||||||
|
Inventories
|
|
|
||||||
|
Prepaid expenses and other current assets
|
|
|
||||||
|
Total current assets
|
|
|
||||||
|
Other assets
|
|
|
||||||
|
Deferred tax assets
|
|
|
||||||
|
Intangible assets, net
|
|
|
||||||
|
Goodwill
|
|
|
||||||
|
Property, Plant, and Equipment:
|
||||||||
|
Land
|
|
|
||||||
|
Buildings
|
|
|
||||||
|
Machinery and equipment
|
|
|
||||||
|
Construction in progress
|
|
|
||||||
|
|
|
|||||||
|
Less accumulated depreciation
|
(
|
(
|
||||||
|
|
|
|||||||
|
Total assets
|
$
|
|
$
|
|
||||
|
Liabilities
and Shareholders’ Equity
|
||||||||
|
Current Liabilities:
|
||||||||
|
Trade accounts payable
|
$
|
|
$
|
|
||||
|
Accrued salaries, wages, and withholdings from employees
|
|
|
||||||
|
Other accrued expenses
|
|
|
||||||
|
Income taxes
|
|
|
||||||
|
Short-term borrowings
|
|
|
||||||
|
Total current liabilities
|
|
|
||||||
|
Deferred tax liabilities
|
|
|
||||||
|
Other liabilities
|
|
|
||||||
|
Accrued employee and retiree benefits
|
|
|
||||||
|
Long-term debt
|
|
|
||||||
|
Shareholders’ Equity:
|
||||||||
|
Common stock
|
|
|
||||||
|
Additional paid-in capital
|
|
|
||||||
|
Earnings reinvested in the business
|
|
|
||||||
|
Treasury stock, at cost
|
(
|
(
|
||||||
|
Accumulated other comprehensive loss
|
(
|
(
|
||||||
|
Total shareholders’ equity
|
|
|
||||||
|
Total liabilities and shareholders’ equity
|
$
|
|
$
|
|
||||
|
Three Months
Ended March 31,
|
||||||||
|
2024
|
2023
|
|||||||
|
Cash flows from operating activities:
|
||||||||
|
Net earnings
|
$
|
|
$
|
|
||||
|
Adjustments to arrive at net cash provided by operating activities:
|
||||||||
|
Depreciation and amortization
|
|
|
||||||
|
Share-based compensation expense
|
|
|
||||||
|
Net (gain) loss on assets
|
(
|
)
|
|
|||||
|
Portfolio Optimization Plan costs
|
||||||||
|
Deferred income taxes
|
(
|
)
|
(
|
)
|
||||
|
Changes in operating assets and liabilities:
|
||||||||
|
Trade accounts receivable
|
(
|
)
|
(
|
)
|
||||
|
Inventories
|
|
(
|
)
|
|||||
|
Prepaid expenses and other assets
|
(
|
)
|
(
|
)
|
||||
|
Accounts payable and other accrued expenses
|
(
|
)
|
(
|
)
|
||||
|
Accrued salaries, wages, and withholdings from employees
|
|
(
|
)
|
|||||
|
Income taxes
|
|
|
||||||
|
Other liabilities
|
|
|
||||||
|
Net cash provided by (used in) operating activities
|
|
(
|
)
|
|||||
|
Cash flows from investing activities:
|
||||||||
|
Acquisition of property, plant, and equipment
|
(
|
)
|
(
|
)
|
||||
|
Proceeds from sale of assets
|
|
|
||||||
|
Other investing activities
|
(
|
)
|
(
|
)
|
||||
|
Net cash used in investing activities
|
(
|
)
|
(
|
)
|
||||
|
Cash flows from financing activities:
|
||||||||
|
Proceeds from additional borrowings
|
|
|
||||||
|
Debt payments
|
(
|
)
|
(
|
)
|
||||
|
Dividends paid
|
(
|
)
|
(
|
)
|
||||
|
Other financing activities
|
(
|
)
|
(
|
)
|
||||
|
Net cash (used in) provided by financing activities
|
(
|
)
|
|
|||||
|
Effect of exchange rate changes on cash and cash equivalents
|
|
|
||||||
|
Net (decrease) increase in cash and cash equivalents
|
(
|
)
|
|
|||||
|
Cash and cash equivalents at beginning of period
|
|
|
||||||
|
Cash and cash equivalents at end of period
|
$
|
|
$
|
|
||||
| |
Treasury Stock
|
|
|
|||||||||||||||||||||||||
|
Three Months
Ended March 31, 2024
|
Common
Stock |
Additional
Paid-In
Capital |
Earnings
Reinvested
in the
Business |
Shares
|
Amount
|
Accumulated
Other
Comprehensive
Income (Loss) |
Total
Equity
|
|||||||||||||||||||||
|
Balances at December 31, 2023
|
$
|
|
$
|
|
$
|
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
|||||||||||||
|
Net earnings
|
|
|
|
-
|
|
|
|
|||||||||||||||||||||
|
Other comprehensive loss
|
|
|
|
-
|
|
(
|
)
|
(
|
)
|
|||||||||||||||||||
|
Cash dividends
paid – $
|
|
|
(
|
)
|
-
|
|
|
(
|
)
|
|||||||||||||||||||
|
Share-based compensation
|
|
|
|
-
|
|
|
|
|||||||||||||||||||||
|
Non-vested stock issued upon vesting
|
|
(
|
)
|
|
(
|
)
|
|
|
|
|||||||||||||||||||
| Benefit plans |
( |
) | ||||||||||||||||||||||||||
|
Other
|
|
(
|
)
|
|
|
(
|
)
|
|
(
|
)
|
||||||||||||||||||
|
Balances at March 31, 2024
|
$
|
|
$
|
|
$
|
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
|||||||||||||
|
Three Months Ended March 31, 2023
|
||||||||||||||||||||||||||||
|
Balances at December 31, 2022
|
$ | $ | $ | $ | ( |
) | $ | ( |
) | $ | ||||||||||||||||||
|
Net earnings
|
- | |||||||||||||||||||||||||||
|
Other comprehensive income
|
- | |||||||||||||||||||||||||||
|
Cash dividends
paid – $
|
( |
) | - | ( |
) | |||||||||||||||||||||||
|
Share-based compensation
|
- | |||||||||||||||||||||||||||
| Non-vested stock issued upon vesting |
( |
) | ( |
) | ||||||||||||||||||||||||
| Benefit plans |
( |
) | ||||||||||||||||||||||||||
| Other |
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||
|
Balances at March 31, 2023
|
$ | $ | $ | $ | ( |
) | $ | ( |
) | $ | ||||||||||||||||||
|
1.
|
Accounting Policies
|
|
2.
|
Portfolio Optimization Plan
|
|
(In thousands)
|
Flavors &
Extracts
|
Color
|
Corporate
& Other
|
Consolidated
|
||||||||||||
|
Non-cash impairment charges – Selling and administrative expenses
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
Non-cash charges – Cost of products sold
|
|
(
|
)
|
|
|
|||||||||||
|
Employee separation – Selling and administrative expenses
|
|
|
|
|
||||||||||||
|
Other costs – Selling and administrative expenses(1)
|
|
|
|
|
||||||||||||
|
Total
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
|
(1) |
|
| 3. |
Trade Accounts Receivable
|
|
(In
thousands)
Three Months Ended March 31, 2024
|
Allowance for
Doubtful Accounts
|
|||
|
Balance at December 31, 2023
|
$
|
|
||
|
Provision for expected credit losses
|
|
|||
|
Accounts written off
|
(
|
)
|
||
|
Translation and other activity
|
(
|
)
|
||
|
Balance at March 31, 2024
|
$
|
|
||
|
(In
thousands)
Three Months Ended March 31, 2023
|
Allowance for
Doubtful Accounts
|
|||
|
Balance at December 31, 2022
|
$
|
|
||
|
Provision for expected credit losses
|
|
|||
|
Accounts written off
|
(
|
)
|
||
|
Translation and other activity
|
|
|||
|
Balance at March 31, 2023
|
$
|
|
||
| 4. |
Inventories
|
| 5. |
Fair Value
|
| 6. |
Segment Information
|
|
(In
thousands)
|
Flavors &
Extracts
|
Color
|
Asia
Pacific
|
Corporate &
Other
|
Consolidated
|
|||||||||||||||
|
Three months ended March 31, 2024:
|
||||||||||||||||||||
|
Revenue from
external customers
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||
|
Intersegment
revenue
|
|
|
|
|
|
|||||||||||||||
|
Total revenue
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||
|
Operating
income (loss)
|
$
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
|
|||||||||
|
Interest
expense
|
|
|
|
|
|
|||||||||||||||
|
Earnings
(loss) before income taxes
|
$
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
|
|||||||||
|
Three months ended March 31, 2023:
|
||||||||||||||||||||
|
Revenue from
external customers
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||
|
Intersegment
revenue
|
|
|
|
|
|
|||||||||||||||
|
Total revenue
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||
|
Operating
income (loss)
|
$
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
|
|||||||||
|
Interest
expense
|
|
|
|
|
|
|||||||||||||||
|
Earnings
(loss) before income taxes
|
$
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
|
|||||||||
|
(In
thousands)
|
Flavors &
Extracts
|
Color
|
Asia Pacific
|
Consolidated
|
||||||||||||
|
Three
months ended March 31, 2024
|
||||||||||||||||
|
Flavors,
Extracts & Flavor Ingredients
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
Natural
Ingredients
|
|
|
|
|
||||||||||||
|
Food &
Pharmaceutical Colors
|
|
|
|
|
||||||||||||
|
Personal Care
|
|
|
|
|
||||||||||||
|
Asia Pacific
|
-
|
-
|
|
|
||||||||||||
|
Intersegment
Revenue
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||||
|
Total revenue
from external customers
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
Three
months ended March 31, 2023:
|
||||||||||||||||
|
Flavors,
Extracts & Flavor Ingredients
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
Natural
Ingredients
|
|
|
|
|
||||||||||||
|
Food &
Pharmaceutical Colors
|
|
|
|
|
||||||||||||
|
Personal Care
|
|
|
|
|
||||||||||||
|
Asia Pacific
|
-
|
-
|
|
|
||||||||||||
|
Intersegment
Revenue
|
(
|
)
|
( |
) |
|
(
|
)
|
|||||||||
|
Total revenue
from external customers
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
(In
thousands)
|
Flavors &
Extracts
|
Color
|
Asia Pacific
|
Consolidated
|
||||||||||||
|
Three months ended March 31, 2024:
|
||||||||||||||||
|
North America
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
Europe
|
|
|
|
|
||||||||||||
|
Asia Pacific
|
|
|
|
|
||||||||||||
|
Other
|
|
|
|
|
||||||||||||
|
Total revenue
from external customers
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
Three months ended March 31, 2023:
|
||||||||||||||||
|
North America
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
Europe
|
|
|
|
|
||||||||||||
|
Asia Pacific
|
|
|
|
|
||||||||||||
|
Other
|
|
|
|
|
||||||||||||
|
Total revenue
from external customers
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
| 7. |
Retirement Plans
|
|
Three Months Ended
March 31,
|
||||||||
|
(In thousands)
|
2024
|
2023
|
||||||
|
Service cost
|
$
|
|
$
|
|
||||
|
Interest cost
|
||||||||
|
Expected return on plan assets
|
(
|
)
|
(
|
)
|
||||
|
Recognized actuarial gain
|
( |
) | ( |
) | ||||
|
Total defined benefit expense
|
$
|
|
$
|
|
||||
| 8. |
Derivative Instruments and Hedging
Activity
|
| 9. |
Income Taxes
|
| 10. |
Accumulated Other Comprehensive Income
|
|
(In thousands)
|
Cash Flow
Hedges (1)
|
Pension
Items (1)
|
Foreign
Currency
Items
|
Total
|
||||||||||||
|
Balances at December 31, 2023
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||||
|
Other comprehensive income (loss) before
reclassifications
|
|
|
(
|
)
|
(
|
)
|
||||||||||
|
Amounts reclassified from OCI
|
(
|
)
|
(
|
)
|
|
(
|
)
|
|||||||||
|
Balances at March 31, 2024
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||||
|
(In thousands)
|
Cash Flow
Hedges (1)
|
Pension
Items (1)
|
Foreign
Currency
Items
|
Total
|
||||||||||||
|
Balances at December 31, 2022
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
||||
|
Other comprehensive income before reclassifications
|
|
|
|
|
||||||||||||
|
Amounts reclassified from OCI
|
(
|
)
|
(
|
)
|
|
(
|
)
|
|||||||||
|
Balances at March 31, 2023
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||||
| (1) |
|
| 11. |
Commitments and Contingencies
|
| 12. |
Subsequent Event
|
| ITEM 2. |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
|
|
Three Months Ended March 31,
|
||||||||||||
|
(In thousands except per share amounts)
|
2024
|
2023
|
% Change
|
|||||||||
|
Operating Income (GAAP)
|
$
|
49,406
|
$
|
50,838
|
(2.8
|
)%
|
||||||
|
Portfolio Optimization Plan costs – Cost of products sold
|
107
|
-
|
||||||||||
|
Portfolio Optimization Plan costs – Selling and administrative expenses
|
2,705
|
-
|
||||||||||
|
Adjusted operating income
|
$
|
52,218
|
$
|
50,838
|
2.7
|
%
|
||||||
|
Net Earnings (GAAP)
|
$
|
30,940
|
$
|
33,651
|
(8.1
|
)%
|
||||||
|
Portfolio Optimization Plan costs, before tax
|
2,812
|
- | ||||||||||
|
Tax impact of Portfolio Optimization Plan costs(1)
|
(355
|
)
|
- | |||||||||
|
Adjusted net earnings
|
$
|
33,397
|
$
|
33,651
|
(0.8
|
)%
|
||||||
|
Diluted Earnings Per Share (GAAP)
|
$
|
0.73
|
$
|
0.80
|
(8.8
|
)%
|
||||||
|
Portfolio Optimization Plan costs, net of tax
|
0.06
|
-
|
||||||||||
|
Adjusted diluted earnings per share
|
$
|
0.79
|
$
|
0.80
|
(1.3
|
)%
|
||||||
|
Three Months Ended March 31, 2024
|
||||||||||||
|
Total
|
Foreign
Exchange
Rates
|
Adjustments(1)
|
Adjusted
Local
Currency
|
|||||||||
|
Revenue
|
||||||||||||
|
Flavors & Extracts
|
8.0%
|
1.1%
|
N/A
|
6.9%
|
||||||||
|
Color
|
(0.7%)
|
1.0%
|
N/A
|
(1.7%)
|
||||||||
|
Asia Pacific
|
0.6%
|
(3.5%)
|
N/A
|
4.1%
|
||||||||
|
Total Revenue
|
4.2%
|
0.4%
|
N/A
|
3.8%
|
||||||||
|
Operating Income
|
||||||||||||
|
Flavors & Extracts
|
6.8%
|
0.5%
|
0.0%
|
|
6.3%
|
|||||||
|
Color
|
(0.6%)
|
1.2%
|
0.0%
|
|
(1.8%)
|
|||||||
|
Asia Pacific
|
(5.0%)
|
(4.4%)
|
0.0%
|
|
(0.6%)
|
|||||||
|
Corporate & Other
|
18.1%
|
0.0%
|
22.5%
|
(4.4%)
|
||||||||
|
Total Operating Income
|
(2.8%)
|
0.2%
|
(5.6%)
|
2.6%
|
||||||||
|
Diluted Earnings per Share
|
(8.8%)
|
0.0%
|
(7.5%)
|
|
(1.3%)
|
|||||||
|
(1)
|
Adjustments consist of Portfolio Optimization Plan costs.
|
| ITEM 3. |
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
|
| ITEM 4. |
CONTROLS AND PROCEDURES
|
| ITEM 1. |
LEGAL PROCEEDINGS
|
| ITEM 1A. |
RISK FACTORS
|
| ITEM 2. |
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
|
| ITEM 5. |
OTHER INFORMATION
|
| ITEM 6. |
EXHIBITS
|
|
Exhibit
|
Description
|
Incorporated by Reference From
|
Filed Herewith
|
|
Certifications of the Company’s Chairman, President & Chief Executive Officer and Senior Vice President & Chief Financial Officer pursuant to Rule 13a-14(a) of the Exchange Act
|
X
|
||
|
Certifications of the Company’s Chairman, President & Chief Executive Officer and Senior Vice President & Chief Financial Officer pursuant to 18 United States Code § 1350
|
X
|
||
|
101.INS
|
Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
|
X
|
|
|
101.SCH
|
Inline XBRL Taxonomy Extension Schema Document
|
X
|
|
|
101.CAL
|
Inline XBRL Taxonomy Extension Calculation Linkbase Document
|
X
|
|
|
101.DEF
|
Inline XBRL Taxonomy Extension Definition Linkbase Document
|
X
|
|
|
101.LAB
|
Inline XBRL Taxonomy Extension Label Linkbase Document
|
X
|
|
|
101.PRE
|
Inline XBRL Taxonomy Extension Presentation Linkbase Document
|
X
|
|
|
104
|
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
|
X
|
|
SENSIENT TECHNOLOGIES CORPORATION
|
||||
|
Date:
|
May 7, 2024
|
By:
|
/s/ John J. Manning
|
|
|
John J.Manning, Senior Vice
|
||||
| President, General Counsel & | ||||
|
Secretary
|
||||
|
Date:
|
May 7, 2024
|
By:
|
/s/ Stephen J. Rolfs
|
|
|
Stephen J. Rolfs, Senior Vice
|
||||
|
President & Chief Financial Officer
|